Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared a post on X:
“OK here it is. Finally. My ASH25 algorithm for Relapsed Myeloma: First Relapse. Discussed with Yi Lin, Shaji Kumar.
Give comments. I’m willing to adjust it based on your insights.”
Hamza Hashmi, Myeloma and Cellular Therapy Physician at Memorial Sloan Kettering Cancer Center, shared this post, adding:
“In MajesTEC-3, only 5% pts were CD38 exposed and none were CD38 Refractory. For a SOC U.S. pt progressing on D plus R, I am not sure if adding Tec to Dara will have the same punch.
On the contrary, ~20% in CARTITUDE-4 were CD38 refractory and had similar benefit from cilta-cel.”
More posts featuring Vincent Rajkumar on OncoDaily.